Symbiotec Pharmalab announced the receipt of an establishment inspection report (EIR) from the U.S. Food and Drug Administration (US FDA) for its manufacturing facility in Pithampur (SEZ), Madhya Pradesh, with a voluntary action indicated (VAI) status.

Symbiotec Pharmalab announced the receipt of an establishment inspection report (EIR) from the U.S. Food and Drug Administration (US FDA) for its manufacturing facility in Pithampur (SEZ), Madhya Pradesh, with a voluntary action indicated (VAI) status.

Symbiotec Pharmalab received an Establishment Inspection Report from the US Food and Drug Administration for its manufacturing facility in Pithampur, Madhya Pradesh, classifying the inspection as Voluntary Action Indicated.

Glenmark Pharmaceuticals received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its Goa facility with a Voluntary Action Indicated (VAI) status.

Glenmark Pharmaceuticals has announced that it has secured an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its formulations manufacturing facility in Goa.

Glenmark Pharmaceuticals has received the establishment inspection report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India.

Glenmark Pharma has received a US FDA EIR for its Goa manufacturing plant, with the June inspection closed under Voluntary Action Indicated status.

Glenmark Pharmaceuticals Ltd announced it received an Establishment Inspection Report from the US health regulator for its Goa facility, which was closed with a Voluntary Action Indicated status.

Glenmark Pharma announced on September 23 that its formulations manufacturing facility in Goa received a Voluntary Action Indicated (VAI) status following an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA).